# US 2025/0249102 A1 · Cmv-hiv specific chimeric antigen receptor t cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0249102 A1
- Document ID: US20250249102A1
- Status: Published application
- Kind: A1
- Application number: 18/856,156
- Filed: 2023-04-13
- Published: 2025-08-07
- Earliest claimed: 2022-04-13
- Assignees: City of Hope
- Applicants: City of Hope
- Inventors: Xiuli Wang; John Zaia; Lihua Elizabeth Budde; Stephen J. Forman; Don J. Diamond
- Web page: https://patentgrep.com/patent/US20250249102A1

## CPC

- A61K 40/46: Viral antigens
- A61P 31/18: for HIV
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/32: T-cell receptors [TCR]
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/089: {Cytomegalovirus}
- C07K 16/114: Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- A61K 2239/17: Hinge-spacer domain
- A61K 2239/21: Transmembrane domain
- A61K 2239/23: On/off switch
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/622: Single chain antibody (scFv)
- C12N 2710/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16111: concerning HIV env
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure relates, inter alia, to compositions comprising and methods making and using T cells expressing both a chimeric antigen receptor (CAR) targeted to HIV and a T cell receptor targeted to cytomegalovirus (CMV).

## Claims

### Claim 1

A nucleic acid molecule encoding a chimeric antigen receptor, wherein the chimeric antigen receptor comprises:
(i) an scFv that binds HIV Env;
(ii) a spacer domain;
(iii) a transmembrane domain;
(iv) a costimulatory domain; and
(v) a CD3ζ signaling domain.

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1, wherein the scFv comprises: a VL domain comprising: a light chain CDR1 comprising QTSQGVGSDLH, a light chain CDR2 comprising HTSSVED, a light chain CDR3 comprising QVLQF; and a VH domain comprising: a heavy chain CDR1 comprising AHILF, a heavy chain CDR2 comprising WIKPQYGAVNFGGGFRD, and a heavy chain CDR3 comprising DRSYGDSSWALDA.

### Claim 3 (depends on 1)

The nucleic acid molecule of claim 1, wherein the scFV comprises:
(a) a light chain variable domain that is at least 90%, 95% or 98% identical to:
YIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHWYQHKPGRAPKLLIH
HTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDIATYYCQVLQFFGRGS
RLHIK;
(b) a heavy chain variable domain that is at least 90%, 95% or 98% identical to:
RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHILFWFRQAPGRGLEWVG
WIKPQYGAVNFGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCAR
DRSYGDSSWALDAWGQGTTVVVSA

### Claim 4 (depends on 3)

The nucleic acid molecule of claim 3, wherein the scFV comprises: a light chain variable domain comprising
YIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHWYQHKPGRAPKLLIH
HTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDIATYYCQVLQFFGRGS
RLHIK;
a heavy chain variable domain comprising
RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHILFWFRQAPGRGLEWVG
WIKPQYGAVNFGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCAR
DRSYGDSSWALDAWGQGTTVVVS.

### Claim 5 (depends on 3)

The nucleic acid molecule of claim 3, wherein the scFv comprises a VL domain that is 95% identical to YIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHWYQHKPGRAPKLLIHHTSSVEDGVPSR FSGSGFHTSFNLTISDLQADDIATYYCQVLQFFGRGSRLHIK and includes the following CDR sequences: QTSQGVGSDLH (VL-CDR1), HTSSVED (VL-CDR2), and QVLQF (VL-CDR3); and a VH domain that is 95% identical to RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHILFWFRQAPGRGLEWVGWIKPQYGAVN FGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVV VSA and includes the following CDR sequences AHILF (VH-CDR1) WIKPQYGAVNFGGGFRD (VH-CDR2), and DRSYGDSSWALDA (VH-CDR3).

### Claim 6

A nucleic acid molecule encoding a chimeric antigen receptor, wherein the chimeric antigen receptor comprises: a scFv comprising or consisting of RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHILFWFRQAPGRGLEWVGWIKPQYGAVN FGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTVV VSAGGGSGGGSGGGSGGGSYIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHWYQHKP GRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDIATYYCQVLQFFGRGSRLHI K; a spacer comprising a sequence selected from the group consisting of: SEQ ID NOs: 24-34; a transmembrane domain comprising a sequence selected from the group consisting of SEQ ID NOs: 15-23; a costimulatory domain comprising a sequence selected from the group consisting of SEQ ID NOs: 36-40, and a CD3ζ signaling domain comprising SEQ ID NO: 35.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The nucleic acid molecule of any of claims 1-6, wherein the spacer region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 24-34.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The nucleic acid molecule of any of claims 1-6, wherein the transmembrane domain selected from the group consisting of:
a CD4 transmembrane domain,
a CD8 transmembrane domain,
a CD28 transmembrane domain, and
a CD3ζ transmembrane domain;

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

The nucleic acid molecule of any of claims 1-6, wherein the costimulatory domain selected from the group consisting of
a CD28 costimulatory domain,
a 41-BB costimulatory domain,
an OX40 costimulatory domain, and
a 2B4 costimulatory domain.

### Claim 10 (depends on 1)

The nucleic acid molecule of claim 1, wherein the chimeric antigen receptor comprises the amino acid sequence RAHLVQSGTAMKKPGASVRVSCQTSGYTFTAHILFWFRQAPGRGLEWVGWIKPQYGAVN FGGGFRDRVTLTRDVYREIAYMDIRGLKPDDTAVYYCARDRSYGDSSWALDAWGQGTTW VSAGGGSGGGSGGGSGGGSYIHVTQSPSSLSVSIGDRVTINCQTSQGVGSDLHWYQHKP GRAPKLLIHHTSSVEDGVPSRFSGSGFHTSFNLTISDLQADDIATYYCQVLQFFGRGSRLHI KESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSQEDPEVQFNW YVDGVEVHNAKTKPREEQFQSTYRWSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKMALIVLGGVAG LLLFIGLGIFFKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELGGGRVKFSR SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQK DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR with 0, 1, 2, 3, 4 of 5 single amino acid substitutions.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6)

The nucleic acid molecule of any of claims 1-6, further comprising an interdomain linker consisting of 1-5 amino acids between one or more of: the scFV and the spacer domain, the spacer domain and the transmembrane domain, the transmembrane domain and the co-stimulatory domain, and the costimulatory domain and the CD3ζ signaling domain.

### Claim 12 (depends on 11)

The nucleic acid molecule of claim 11, wherein interdomain linker consists of 1-5 glycine.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6)

The nucleic acid molecule of any of claims 1-6, wherein an interdomain linker consisting of the sequence GGG is located between the costimulatory domain and the CD3ζ signaling domain.

### Claim 14

An immune cell harboring the nucleic acid molecule of any of the forgoing claims.

### Claim 15 (depends on 14)

The immune cell of claim 14, wherein the cell is a T cell expressing a T cell receptor specific for CMV (CMV specific T cell).

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A population of cells comprising CMV specific T cells harboring the nucleic acid molecule of any of claims 1-13.

### Claim 17 (depends on 16)

The population of cells of claim 16, wherein at least 50% of the CMV specific T cells are CD8+ T cells.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A method of preparing the population of CMV specific T cells expressing an HIV CAR, the method comprising: isolating a cell population comprising PBMC from a blood sample obtained from a CMVpos subject; contacting the cell population with a CMV antigen to stimulate CMV specific T cells; isolating a sub-population of IFNγ-secreting T cells (e.g., CMV specific cells) from the cell population; and transducing cells in the sub-population of IFNγ-secreting T cells with a vector comprising the nucleic acid molecule of any of claims 1-14.

### Claim 19 (depends on 18)

The method of claim 18, wherein the sub-population of IFNγ-secreting T cells are cultured in the presence of one or both of exogenous IL-2 and exogenous IL-15 before transduction, after transduction or both before and after transduction.

### Claim 20 (depends on 19)

The method of claim 19, wherein IL-2 is added to at 50 U/mL and IL-15 is added to 1 ng/mL.

### Claim 21 (depends on 19)

The method of claim 19, wherein the sub-population of IFNγ-secreting T cells are cultured in the presence of at least one or both of an HIV protease inhibitor and an HIV entry/fusion inhibitor and not in the presence of a reverse transcriptase inhibitor before transduction, after transduction or both before and after transduction.

### Claim 22 (depends on 21)

The method of claim 21, wherein the sub-population of IFNγ-secreting T cells are cultured in the presence of darunavir and enfuvirtide.

### Claim 23 (depends on 18, 19)

The method of any of claims 18-19, wherein the blood sample is from a subject infected with HIV.

### Claim 24

A method for treating a subject infected with HIV, the method comprising administering: (a) a population of CMV-specific T cells expressing chimeric antigen receptor comprising: an scFv that binds HIV Env; a spacer domain; a transmembrane domain; a costimulatory domain; and a CD3ζ signaling domain; and, optionally, (b) at least one CMV antigen or a nucleic acid molecule encoding at least one CMV antigen.

### Claim 25 (depends on 24)

The method of claim 24, wherein the at least one CMV antigen comprises at least one of a CMV protein, a fragment of a CMV protein, a modified CMV protein, a fragment of a modified CMV protein, a mutated CMV protein or a fragment thereof, a fusion CMV protein or a fragment thereof, and combinations thereof.

### Claim 26 (depends on 24)

The method of claim 24, wherein the at least one CMV antigen comprises at least one of pp65, IE1 exon 4 (IE1/e4), IE2 exon 5 (IE2/e5), fusions thereof, antigenic fragments thereof, and variants thereof having 1, 2, 3, 4, or 5 amino acid modifications.

### Claim 27 (depends on 24)

The method of claim 24, wherein the at least one CMV antigen comprises a CMVpp65 peptide.

### Claim 28 (depends on 24)

The method of claim 24, wherein the nucleic acid molecule comprises a viral vector encoding (a) a CMV pp65 peptide or protein and (b) a fusion protein comprising exon 4 of CMV protein 1E1 (e4) and exon 5 of CMV protein 1E2 (e5).

### Claim 29 (depends on 24)

The method of claim 24, wherein the at least one antigen comprises at least one sequence selected from SEQ ID NOs: 57-64 and variants thereof having 1, 2, 3, 4, or 5 amino acid modifications.

### Claim 30 (depends on 24)

The method of claim 24, wherein the at least one CMV antigen comprises at least one fragment of any of SEQ ID NOs: 57-64, wherein the fragment comprises of consists of at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, or 42 contiguous amino acids of any of SEQ ID NOs: 57-64.

### Claim 31 (depends on 24)

The method of claim 24, wherein the at least one CMV antigen or a nucleic acid molecule encoding at least one CMV antigen is administered prior to or subsequent to administering the population of CMV-specific T cells.

### Claim 32 (depends on 31)

The method of claim 31, wherein the at least one CMV antigen or a nucleic acid molecule encoding at least one CMV antigen is administered about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, 21, 22, 23, 24, 25, 26, 28, 36, 48, 60, 75, 90, 120, 150, 180, 210, 240, 270, 300, 330, and/or 360 hours prior to administering the population of CMV-specific T cells.

### Claim 33 (depends on 31)

The method of claim 31, wherein the at least one CMV antigen or a nucleic acid molecule encoding at least one CMV antigen is administered about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, 18, 20, 21, 22, 23, 24, 25, 26, 28, 36, 48, 60, 75, 90, 120, 150, 180, 210, 240, 270, 300, 330, and/or 360 days subsequent to administering the population of CMV-specific T cells.

### Claim 34 (depends on 24)

The method of claim 24, wherein the at least one CMV antigen or a nucleic acid molecule encoding at least one CMV antigen is administered in an amount sufficient to illicit an immune response in the subject.

### Claim 35 (depends on 24)

The method of claim 24, wherein the CAR comprises: a scFv comprising or consisting of SEQ ID NO:9 or a variant thereof having 1, 2, 3, 4, or 5, amino acid substitutions that are not in a CDR; a spacer comprising a sequence selected from the group consisting of: SEQ ID NOs: 24-34 or a variant thereof having 1, 2, 3, 4, or 5, amino acid substitutions; a transmembrane domain comprising a sequence selected from the group consisting of SEQ ID NOs: 15-23 or a variant thereof having 1, 2, 3, 4, or 5, amino acid substitutions; a costimulatory domain comprising a sequence selected from the group consisting of SEQ ID NOs: 36-40 or a variant thereof having 1, 2, 3, 4, or 5, amino acid substitutions; and a CD3ζ signaling domain comprising SEQ ID NO: 35 or a variant thereof having 1, 2, 3, 4, or 5, amino acid substitutions.

### Claim 36 (depends on 24)

The method of claim 24, wherein the CAR comprises SEQ ID NO:10 or a variant thereof having 1, 2, 3, 4, or 5, amino acid substitutions, wherein the amino acid substitutions are not in the CDRs.

### Claim 37 (depends on 24)

The method of claim 24, wherein the population of CMV-specific T cells is at least 40%, 50%, 60%, or 70% IFN-γ positive.

### Claim 38 (depends on 24)

The method of claim 24, wherein the population of CMV-specific T cells is at least 20%, 30%, 35% CD8 positive.

### Claim 39 (depends on 24)

The method of claim 24, wherein the population of CMV-specific T cells is at least 20%, 25%, 30%, 35% CD4 positive.

### Claim 40 (depends on 24)

The method of claim 24, wherein the population of CMV-specific T cells is at least 40% IFN-γ positive, at least 20% CD8 positive, and at least 20% CD4 positive.

### Claim 41 (depends on 24)

The method of claim 24, wherein the population of CMV-specific T cells is at least 20% CD8 positive and at least 20% CD4 positive.

### Claim 42 (depends on 41)

The method of claim 41, wherein the population of CMV-specific T cells is at least 30% CD8 positive and at least 30% CD4 positive.
